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For most viruses, there is a need for antimicrobials
that target unique viral molecular properties. Acyclo-
vir (ACV) is one such drug. It is activated into a human
herpesvirus (HHV) DNA polymerase inhibitor exclu-
sively by HHV kinases and, thus, does not suppress
other viruses. Here, we show that ACV suppresses
HIV-1 in HHV-coinfected human tissues, but not in
HHV-free tissue or cell cultures. However, addition
of HHV-6-infected cells renders these cultures sensi-
tive to anti-HIV ACV activity. We hypothesized that
such HIV suppression requires ACV phosphorylation
by HHV kinases. Indeed, an ACV monophosphory-
lated prodrug bypasses the HHV requirement for
HIV suppression. Furthermore, phosphorylated ACV
directly inhibits HIV-1 reverse transcriptase (RT), ter-
minating DNA chain elongation, and can trap RT at
the termination site. These data suggest that ACV
anti-HIV-1 activity may contribute to the response
of HIV/HHV-coinfected patients to ACV treatment
and could guide strategies for the development of
new HIV-1 RT inhibitors.
INTRODUCTION
HIV-1 infection is usually accompanied by infection with other
microbes, HIV-1 copathogens, which either pre-exist in the hu-
man body or invade it de novo. The replication of HIV-1 copath-
ogens is frequently promoted in HIV-1-infected hosts, and their
suppression is often beneficial for the clinical course of HIV dis-
ease (Corey, 2007; Jacobson and Mills, 1988). Human herpesvi-
rus (HHV) infections are commonly associated with HIV-1. In par-
ticular, herpes simplex virus 2 (HSV-2) infection is associated260 Cell Host & Microbe 4, 260–270, September 11, 2008 ª2008 Elwith an increase in HIV-1 transmission (Cohen, 2004; Freeman
et al., 2006) and worsens the clinical course of HIV disease.
HSV-2 reactivation may lead to increased plasma HIV-1 levels,
thereby adversely affecting survival rates (Corey et al., 2004;
Schacker et al., 2002).
Acyclovir (ACV) is a guanosine nucleoside analog particularly
active against HSV-2 as well as against the other a-HHVs
(HSV-1 and VZV) (Elion, 1983). It also inhibits, although with
lower potency, the replication of the b-HHVs (CMV, HHV-6,
and HHV-7) and of the g-HHVs (EBV and HHV-8) (De Clercq
et al., 2001).
The mechanism of HHV suppression by ACV is well under-
stood. ACV is phosphorylated in HHV-infected cells by viral-
encoded kinases. The resulting monophosphate derivative
(ACV-MP) is then converted into ACV triphosphate (ACV-TP)
by cellular enzymes and is subsequently incorporated by the
viral DNA polymerase into the nascent viral DNA chain, caus-
ing its obligate termination (Reardon and Spector, 1989). Gen-
erally, the sensitivity of different HHVs to ACV is determined
by the extent of its phosphorylation by HHV kinase and by
the rate of incorporation of ACV-TP into the viral DNA chain
(De Clercq et al., 2001). The mechanism described above ex-
plains why ACV does not directly affect viruses other than
HHVs, including HIV-1. Nevertheless, early clinical trials indi-
cated that ACV treatment may result in survival benefits in co-
horts of HIV-1-infected patients with a high incidence of clin-
ically identifiable HHV (Ioannidis et al., 1998). In agreement
with these data, recent trials showed that, in HSV-2-coin-
fected individuals, the suppression of HSV-2 by ACV is ac-
companied by reduction of the plasmatic, genital, and rectal
HIV-1 load (Baeten et al., 2007; Delany et al., 2007; Dunne
et al., 2008; Nagot et al., 2007; Zuckerman et al., 2007).
This decrease was attributed to the suppression of HSV-2-
mediated inflammation indirectly reducing HIV-1 load.
Here, we report on the direct activity of ACV on HIV-1 and,
specifically, on the inhibition of HIV-1 reverse transcriptasesevier Inc.
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Acyclovir Inhibits HIV-1 Reverse Transcriptase(RT) by ACV-TP. We demonstrate that, consequently, ACV is an
anti-HIV-1 agent in human lymphoid, rectal, and genital tissues,
which are widely infected with one or more HHVs that are able to
phosphorylate ACV.
RESULTS
ACV Suppresses HIV Replication in Human Lymphoid
Tissue Coinfected Ex Vivo with HSV-2
In this study, we used an ex vivo system that preserves the cy-
toarchitecture of human tissues and supports replication of var-
ious viruses without exogenous stimulation (Glushakova et al.,
1995).
Initially, we inoculated tissues with HIV-1LAI.04 and HSV-2
(strain G). Both viruses readily replicated in tissues. As expected,
ACV at a concentration of 30mM suppressed HSV-2 replication in
both HSV-2 singly infected and HIV-1 coinfected tissues (by 97 ±
1.8% and 93 ± 5.8%, respectively, p = 3 3 105, p = 5 3 104,
n = 4). However, in these HSV-2-coinoculated tissues, ACV
also suppressed HIV-1 replication by 62 ± 4.2% (p = 2 3 103,
n = 4) (Figure 1A).
ACV Suppresses HIV Replication in Singly Infected
Human Lymphoid Tissue Ex Vivo
Surprisingly, ACV was also found to suppress HIV-1 replication
in tonsillar tissues from 38 donors that were not coinoculated
with HSV-2 (Figures 1B–1D).
In HIV-1 singly infected tissues, the suppression of HIV-1 rep-
lication, measured as p24gag accumulation in culture medium,
was dose dependent with a 50% effective concentration (EC50)
of 3.1 mM (95% confidence interval: 1.85–5.24) (Figure 1B).
HIV-1 replication, evaluated by the measurement of HIV-1 provi-
ral DNA in tissue blocks at day 12 postinfection, was reduced by
94.8% (interquartile range [IQR] 65.9%–99.8%) in blocks of ton-
sillar tissues treated with ACV at the concentration of 30 mM
compared with donor-matched untreated blocks. The median vi-
ral load was reduced by 1.3 log10, from 3108 gag DNA copies
per 104 cells in untreated tissues (3.49 log10; IQR 2.99–4.01) to
162 gag DNA copies per 104 cells in ACV-treated tissues (2.27
log10; IQR 0.09–3.07, p < 10
4, n = 27) (Figure 1C). Consistently,
ACV significantly decreased the amount of p24gag released into
the culture medium on average by 80 ± 4% (p < 73 107, n = 38)
in human tonsillar tissues (Figure 1D). The average cumulative
production of p24gag in the culture medium of tonsillar tissues
was 46.4 ± 8 ng/ml and 16.6 ± 4.6 ng/ml, respectively, in tissues
untreated and treated with 30 mM ACV.
To avoid the possible confounding effects of contaminating
products in commercial ACV, we used ACV from three sources
and found that all of them similarly suppressed HIV (p R 0.45,
n = 4). Suppression of HIV-1 replication by ACV was not associ-
ated with T cell depletion, as evidenced from the similar numbers
of total T cells (CD4+CD3+ and CD8+CD3+, p R 0.5, n = 3) and
their subsets of activated (CD25+, HLA-DR+, or CD38), naive
(CD45RA+CD62L+), or nonnaive (CD45RACD62L+/) (p R
0.16, n = 3) cells. Moreover, ACV antiviral activity was restricted
to HSV-2 and HIV-1 since, as expected, ACV did not reduce vac-
cinia virus replication in tonsillar tissue ex vivo (data not shown).Cell HostACV Suppresses Replication of CCR5- and CXCR4-
Tropic HIV-1 Variants in Various Human Tissues
To test whether ACV suppressed HIV-1 replication in tissues
other than tonsils, we used explants of tissues that also play
an important role in HIV transmission and pathogenesis in vivo:
lymph nodes and cervicovaginal and colorectal tissues. ACV
suppressed HIV-1 replication, measured by p24gag accumula-
tion in culture medium, in lymph nodes by 70 ± 13.9% (p = 2 3
103, n = 7), in colorectal tissues by 72.6 ± 9% (p = 2 3 102,
n = 3), and in cervical tissues by 60.1 ± 3.5% (p = 7 3 103,
n = 3). ACV treatment of ex vivo human lymph nodes reduced
the average cumulative production of p24gag in culture medium
from 67.3 ± 28.1 ng/ml to 15.4 ± 6.6 ng/ml, in ex vivo human co-
lorectal tissues from 7.2 ± 6.8 ng/ml to 1.3 ± 1.2 ng/ml (n = 3), and
in ex vivo human cervicovaginal tissues from 3.8 ± 1.7 ng/ml to
1.4 ± 0.5 ng/ml (n = 3) (Figure 2A).
Furthermore, we evaluated the efficiency of ACV in suppress-
ing different HIV-1 variants. We inoculated ex vivo lymphoid tis-
sues with CCR5- and CXCR4-tropic HIV-1 variants X4LAI.04,
R5SF162, R5BaL, and R5AD8. As shown in Figure 2B, ACV sup-
pressed replication of all of these isolates in tonsillar tissues
with similar efficiency (by 88%, 95%, 89%, and 94%,
respectively, as assessed from p24gag production).
Coinfection with Different Endogenous Human
Herpesviruses Is Associated with the Anti-HIV Effect
of ACV
To test whether suppression of HIV by ACV is related to the anti-
herpetic activity of this drug, we measured the presence of var-
ious HHVs in the tonsillar tissues used in the present work
(Figure 2C). Real-time PCR analysis revealed that all 27 tonsillar
tissues that were tested for the presence of HHVs were negative
for HSV-1, HSV-2, HHV-3 (VZV), and HHV-8 but were infected
with HHV-4 (EBV), -5 (CMV), -6, and -7 in various combinations
(Figure 2C). CMV was present in 15% of tissues; EBV, in 52%;
HHV-7, in 89%; and HHV-6, in all but one tissue (96%).
Similar to what was observed in immunocompromised pa-
tients (Lusso and Gallo, 1994), HHV load was increased in tis-
sues ex vivo. There was a 5-fold increase in the median HHV-
6 load at day 12 in culture, from 22.4 DNA copies per 104
cells at the time of surgery (IQR 1.8–57.7) to 116.6 DNA cop-
ies per 104 cells (IQR 33.7–808, p = 3 3 104, n = 26). After
ACV treatment, the median HHV-6 load at day 12 was re-
duced to 55.1 DNA copies per 104 cells (IQR 21.3–334.6,
p = 102, n = 26), demonstrating that ACV significantly sup-
pressed HHV-6 replication. The sensitivity of HHV-6 to ACV
was further evaluated in separate experiments in which
ex vivo tonsillar tissues were inoculated with HHV-6B (PL-1
strain). In these experiments, ACV suppressed HHV-6B repli-
cation in a dose-dependent manner with an EC50 of 27 mM.
We found that ACV reduced the total production of HHV-6B
in culture medium on average by 56.2 ± 11.4% (52.2 ± 12.4
3 108 DNA copies per ml versus 22.5 ± 9.4 3 108 DNA cop-
ies per ml in control and ACV-treated tissues, respectively;
p = 3 3 103, n = 3).
HHV-7, HHV-4, and HHV-5 median loads in tonsillar tissues
were, respectively, 9.23 (IQR 0.51–56.81), 4.71 (IQR 0.06–
448.3), and 0.1 (IQR 0.06–0.1) DNA copies per 104 cells at
the time of surgery and 21.87 (IQR 0.9–219.7, n = 24), 31.16& Microbe 4, 260–270, September 11, 2008 ª2008 Elsevier Inc. 261
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per 104 cells after 12 days of culture.
In all tissues infected with different combinations of HHVs,
ACV suppressed HIV-1 replication with a similar efficiency (Fig-
ure 2C). HHV-6 was the only HHV that was present in all combi-
nations. Moreover, it seems that the suppression of HIV-1 by
ACV is related to the amount of HHV-6. In tissue blocks in which
ACV inhibited HIV-1 replication by more than 50%, the median
HHV-6 load on day 12 in culture was significantly higher than
in the tissues in which ACV suppressed HIV-1 replication by
less than 50%: 131.1 DNA copies per 104 cells (IQR 36.1–
1154, n = 23) versus 21.6 DNA copies per 104 cells (IQR 0.6–
77.4, n = 4; p = 4 3 102), respectively. Furthermore, we docu-
mented a correlation between the ACV-mediated suppression
of HIV-1 replication, as measured by p24gag release, and the
level of HHV-6 in tissues where the HIV-1 inhibition was
suboptimal (between 0 and 99%; r = 0.43, p = 0.03, n = 25).
Although several HHVs, such as HHV-6, are ubiquitous and
transmitted early in childhood, we identified a tissue in which
there was no detectable HHV. In agreement with our hypothesis,
in this tissue, ACV suppression of HIV-1 (at the concentration of
30 mM) was negligible (16%) (Figure 2C).
Coinfection with HHVs Is Necessary and Sufficient
for the Anti-HIV Effect of ACV
To prove this claim, we performed experiments with MT4 cells,
an HHV-uninfected T cell line that efficiently supports the rep-
lication of HIV-1LAI.04. We found that ACV did not suppress
Figure 1. ACV Suppresses HIV Infection in Human Tonsillar Tissues
(A) Blocks of human tonsillar tissue were coinoculated ex vivo with HSV-2 strain G and X4LAI.04 and treated or not with ACV (30 mM). HIV-1 replication was mon-
itored by measuring p24gag accumulated in culture media over 3 day periods. Presented are means ± SEM of the results with tissues from 4 to 17 donors. For each
donor, each data point represents pooled viral release from 27 tissue blocks. Note that ACV suppresses HIV-1 in HSV-2-coinfected tissues.
(B) HIV-1 replication was measured in tonsillar blocks infected with X4LAI.04 as in (A). ACV was added at the concentrations of 0.3, 3, 10, 30, and 100 mM, and its
anti-HIV activity was evaluated from the suppression of viral replication compared with donor-matched HIV-infected tissues not treated with ACV. The 50% ef-
fective concentration (EC50) was estimated by fitting the data to four-parameter logistic regression and was estimated to be 3.1 mM (95% confidence interval:
1.85–5.24). Presented are means ± SEM of the results with tissues from three to seven donors. Note that ACV suppresses HIV-1 replication in the tonsillar tissues
in a dose-dependent manner.
(C) HIV-1 proviral DNA load in tissue blocks at day 12 postinfection was measured by real-time PCR. Presented are medians and interquartile ranges of the results
(n = 27). Note that ACV efficiently reduces HIV-1 proviral DNA load in blocks of tonsillar tissue.
(D) HIV-1 replication was monitored as in (A). Presented are means ± SEM of the results (n = 38). Note that ACV efficiently suppresses HIV-1 replication in the
tonsillar tissues tested.
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Acyclovir Inhibits HIV-1 Reverse TranscriptaseHIV-1LAI.04 (EC50 > 250 mM) in these cultures, in agreement with
earlier observations (Barral et al., 2003). To test whether HHV in-
fection is sufficient for the anti HIV-1 effect of ACV, we added
various amounts of HHV-6B-infected MT4 cells to HHV-free
MT4 cultures infected with HIV-1LAI.04. As expected, ACV sup-
pressed HHV-6. After 3 days of culture, the fraction of HHV-
6B-infected cells was reduced in a dose-dependent manner,
as measured by flow cytometry (Figure 3A). Importantly, in these
cultures, ACV suppressed HIV replication as well, as evaluated
by the number of p24gag
+ T cells and p24gag release into the culture
medium (EC50 of 50 mM) (Figures 3A and 3B). In these experi-
ments, 9% of HHV-6B-infected cells were sufficient to suppress
HIV-1LAI.04 replication by 70% (Figure 3A). We found that, in
agreement with earlier publications (De Clercq et al., 2001), the con-
centration that corresponds to the EC50 in these experiments did
not affect cell viability (50% cytotoxic concentration > 250 mM).
To further prove that ACV phosphorylation is required for HIV-
1 inhibition, we synthesized the monophosphorylated ACV
prodrug acyclovir-(1-naphthyl [methoxy-L-alaninyl]) phosphora-
midate (Cf2649) (Figure 3C). This compound bypasses the re-
quirement of HHVs for the activation of ACV since it is already
monophosphorylated. Indeed, when applied to (HHV-free) MT-
4 cells, Cf2649, in contrast to nonphosphorylated ACV (EC50 >
250 mM), suppressed HIV-1 replication with an EC50 of 3 mM
(Figures 3D and 3E). Similar results were obtained with another
HHV-free T cell line (CEM) (data not shown).
In conclusion, we demonstrated that neither in HHV-free tissue
nor in HHV-free cell lines does ACV suppress HIV-1 infection.
Reconstitution of the cell line system with HHV-6-infected cells
or bypassing the HHV-kinases requirement by applying an
ACV monophosphate derivative makes HHV-free systems
susceptible to HIV suppression by ACV.
ACV-TP Inhibits HIV-1 RT
Since we demonstrated that the anti-HIV-1 activity of ACV re-
quires HHV-mediated activation and that phosphorylated deriv-
atives of ACV are produced in HHV-infected tissues (see Supple-
mental Data and Figure S1 available online), we hypothesized
that ACV-TP, into which ACV is ultimately converted (Elion,
1983), interferes with the activity of the HIV-1 RT and directly
suppresses HIV-1 replication.
We tested whether ACV-TP suppresses RT by measuring the
polymerizing activity of RT from lysed HIV-1 using an exoge-
nously added HIV-1 template. We observed a dose-dependent
inhibition of HIV-1 RT activity by ACV-TP, while we noted no sup-
pression of HIV-1 RT activity by ACV itself, even at high concen-
trations (Figure 4A).
Figure 2. ACV Suppresses Replication of Different HIV-1 Variants in Human Tissues Coinfected with Various HHVs
(A) HIV-1 replication in blocks of human lymph nodes and colorectal and cervicovaginal tissues was monitored as in Figure 1A. For each type of tissue, the graph
represents a typical result of three to seven experiments performed with tissues from different donors. Note that ACV efficiently suppresses replication of HIV-1 in
lymph nodes and colorectal and cervicovaginal tissues.
(B) Examples of ACV suppression of different HIV-1 variants (X4LAI.04, R5BaL, R5SF162, and R5AD8). Each data point represents pooled viral release from 27 tissue
tonsillar blocks. Note that ACV efficiently suppresses replication of all four HIV-1 variants.
(C) Presence of HHV-1, -2, -3, -4, -5, -6, -7, and -8 by real-time PCR in blocks of tonsillar tissue. All tissues were negative for HHV-1, -2, -3, and -8. Presented are
means ± SEM of the results with tonsils from n donors. Note that there are no significant differences in the level of ACV suppression of HIV-1 replication in tissues
infected with various HHVs.
Cell Host & Microbe 4, 260–270, September 11, 2008 ª2008 Elsevier Inc. 263
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Acyclovir Inhibits HIV-1 Reverse TranscriptaseSince ACV-TP is a guanosine-50-triphosphate analog, we
investigated whether it acts as a nucleotide RT inhibitor
by testing whether dGTP prevents ACV-TP inhibition of RT.
We found that, at ACV-TP concentrations of 3.38 mM or
33.8 mM, HIV-1 RT inhibition was inversely dependent on
the dGTP concentrations. At the highest concentration of
ACV-TP tested, no competition with dGTP was observed
(Figure 4B). Since ACV-TP lacks an additional hydroxyl group
(present in dGTP and essential for DNA chain polymerization),
we further hypothesized that the above-described suppres-
sion of HIV-1 RT by ACV-TP is similar to its suppression of
HSV DNA polymerase, namely by incorporation into the
nascent HIV DNA resulting in its chain termination (Reardon
and Spector, 1989).
To prove this hypothesis, we used a gel-based assay (March-
and and Gotte, 2003; Marchand et al., 2007) and found that HIV-
1 RT incorporated ACV-TP into the DNA primer as efficiently as
the natural substrate dGTP. The efficiency of single-nucleotide
incorporation events (kcat/Km) under steady-state conditions
for dGTP and ACV-TP was 14.7 mM1min1 and 14.0
mM1min1, respectively (Table S1). Furthermore, ACV-TP in-
corporation resulted in complete DNA chain termination, as
shown in Figures 5A and 5B. A primer that contained the natural
dGMP at its 30 end was successfully extended in the presence of
dTTP, which is the substrate for the following three consecutive
template positions (Figure 5B, left panel). In contrast, DNA syn-
thesis was effectively blocked when the primer was terminated
with ACV-MP. Even the relatively high concentration of 50 mM
of dTTP did not permit its incorporation (Figure 5B, right panel).
These data suggest that the mechanism of action of ACV is
similar to the currently approved anti-HIV nucleoside reverse
transcriptase inhibitors (NRTIs).
Figure 3. ACV Suppresses HIV-1 in HHV-Free MT-4 Cell Cultures Either in the Presence of HHV-6-Infected Cells or as Monophosphorylated
Prodrug
(A) HIV-1LAI.04-infected MT4 cells were cocultured with HHV-6B-infected MT4 cells in a ratio of 10:1. Presented are the distributions of HHV-6B (upper panel) and
HIV-1LAI.04-infected cells (lower panel), as measured by flow cytometry at day 3 post-HIV-1 infection, in cultures untreated or treated with various concentrations
of ACV. Note that the fraction of both HHV-6B- and HIV-1-infected cells is reduced in a dose-dependent manner by ACV treatment.
(B) HIV-1LAI.04-infected MT4 cells were cocultured with HHV-6B-infected MT4 cells. HIV-1 replication was monitored as in Figure 1A. Note that the replication of
HIV-1 in HHV-6B-/HIV-1-infected cocultures is suppressed by ACV treatment in a dose-dependent manner.
(C) The compound acyclovir-(1-naphthyl [methoxy-L-alaninyl]) phosphoramidate (Cf2649) has been synthesized as described in the Supplemental Data.
(D) HIV-1LAI.04-infected HHV-free MT4 cells were treated with various concentrations of the ACV monophosphorylated prodrug Cf2649. Presented are the kinetics
of HIV-1LAI.04 replication, monitored by measuring p24gag accumulated in culture media at days 2, 3, 4, and 6 postinfection. Presented data are representative of
two experiments. Note that compound Cf2649 suppresses the replication of HIV-1LAI.04 in a dose-dependent manner.
(E) HIV-1LAI.04-infected MT4 cells not infected with any HHVs were treated with various concentrations of the compound Cf2649. The cumulative release of p24gag
into culture media over 6 days of culture treated with various concentrations of the compound Cf2649 is presented as a fraction of the p24gag production in the
untreated cultures. Presented data are representative of two independent experiments. Note that compound Cf2649 suppresses the replication of HIV-1LAI.04 in
a dose-dependent manner.
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Acyclovir Inhibits HIV-1 Reverse TranscriptaseDNA chain termination by NRTIs is not irreversible but can be
subjected to phosphorolytic excision of the incorporated drug by
HIV RT (Meyer et al., 1998). Binding of the next complementary
nucleotide following the DNA chain terminator can lead to the
formation of a dead-end complex (DEC). In this complex, HIV
RT is trapped in a conformation that blocks the excision reaction.
Thus, to test whether ACV-MP-terminated DNA is accompanied
with the formation of a dead-end complex, we evaluated the in-
hibition of ACV-MP phosphorolytic excision from the 30 end of
the primer by HIV-1 RT. The excision of a DNA chain terminator
requires the presence of pyrophosphate (PPi) or pyrophosphate
donor molecules (such as ATP). We found that HIV-1 RT is capa-
ble of excising the incorporated ACV-MP in the presence of
physiologically relevant concentrations of ATP (data not shown)
as demonstrated for certain NRTIs. However, to analyze whether
the ACV-terminated primer permits formation of a dead-end
complex, the ATP-dependent excision reaction was assayed in
the presence of increasing concentrations of the next comple-
mentary nucleotide. We found that the next complementary nu-
cleotide caused 50% inhibition of ACV-MP excision (IC50) at
a concentration of 26 mM (Figures 6A and 6B). These data
strongly suggest the formation of a dead-end complex in ACV-
MP-incorporated templates. The higher IC50 (26 mM versus
3.1 mM) in comparison to reactions conducted with the control
DNA chain terminator ddGMP was probably due to the acyclic
nature of ACV-MP. In general, the excision reaction was ineffi-
cient; only 10%–15% of the terminated primer strands were res-
cued for continuation of DNA synthesis at low concentrations of
the next complementary nucleotide.
To provide additional direct evidence of dead-end complex
formation, we employed site-specific footprinting that allowed
us to determine the position of HIV-1 RT on its primer/template
at single-nucleotide resolution (Marchand and Gotte, 2003;
Marchand et al., 2007). Nucleotide binding and formation of
a dead-end complex can only occur in the posttranslocated con-
formation in which the nucleotide-binding site of HIV-1 RT has
Figure 4. ACV-TP Inhibits HIV-1 RT in Exogenous Template Reverse
Transcriptase Assays
(A) Exogenous template reverse transcriptase assays were performed in the
presence of various concentrations of ACV or ACV-TP as described in the
Experimental Procedures. Presented are means ± SEM of the results of two
experiments performed in duplicates. Note that ACV-TP inhibits HIV-1 RT
in a dose-dependent manner.
(B) The dependence of the RT inhibition by ACV-TP on the concentration of
dGTP was evaluated using an exogenous template reverse transcriptase as-
say. dGTP was used at the indicated concentrations. The reactions were per-
formed in the presence of the indicated concentrations of ACV-TP. Presented
are means ± SEM of the results of two experiments performed in duplicate.
Note that inhibition of HIV-1 RT activity by ACV-TP is inversely dependent
on the concentration of dGTP.
Figure 5. Chain Termination with ACV-MP
(A) The reaction scheme shows the relevant region of the primer and template
and two possible outcomes of the primer elongation. Elongation of the primer
in the presence of dGTP or ACV-TP is indicated by the ‘‘Z’’ in red, which refers
to the incorporated monophosphate dGMP or ACV-MP, respectively.
Incorporation events following position Z with dTTP are in blue and underlined.
(B) The primer (S, lane C) was initially elongated to incorporate dGMP or ACV-
MP, respectively, at the 30 end referred to as Z. Incubation with increasing con-
centrations of the next nucleotide dTTP resulted in three nucleotide incorpora-
tion events with the dGMP-terminated primer, which are labeled as products
(P). Note that the ACV-MP-terminated primer is not extended, which shows
that the inhibitor acts as a chain terminator.
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Acyclovir Inhibits HIV-1 Reverse Transcriptasebeen cleared. In this conformation, the RT has moved a single
nucleotide further downstream relative to the pretranslocated
state. Our footprints are based on oxidative cleavage on the tem-
plate strand at positions 17 and 18, which are indicative of
post and pretranslocated complexes, respectively. We com-
pared footprints of complexes with ddGMP- and ACV-MP-termi-
nated primers in the presence of increasing concentrations of the
next complementary nucleotide (Figure 6C). Low concentrations
of the next complementary nucleotide are sufficient to stabilize
the posttranslocated complex when the primer was terminated
with ddGMP, proving the formation of a dead-end complex. A
similar pattern is seen with ACV-MP, although the concentration
of the next nucleotide required to stabilize the complex is higher.
Oxidative cleavage in case of ACV-MP did not occur in the ab-
sence of or at low concentrations of the next complementary
nucleotide. These findings suggest that, at the low next comple-
mentary nucleotide concentration, the complex between RT and
terminated primer formed at the site of the ACV-MP termination
is relatively fragile—perhaps prone to dissociation. In contrast, at
high concentration of the next complementary nucleotide, RT
can be trapped in a dead-end complex. The dissociation con-
stant for ACV-terminated primers in the presence of a high con-
centration of the next nucleotide (111 mM) is increased 3-fold
(Figure S2).
Thus, these data explain why the excision of ACV-MP is gen-
erally inefficient at both low and high concentrations of the next
complementary nucleotide. At low concentrations, the complex
between RT and ACV-MP is relatively unstable, while, at higher
concentrations, a DEC is formed.
To prove that ACV targets HIV-1 RT in human tissues as in cell-
free assays, we tested two pairs of HIV isogenic strains that are
resistant to some of the currently approved NRTIs. The isolate
Figure 6. Inhibition of ATP-Dependent Excision in the Presence of the Next Nucleotide Substrate
ATP-dependent excision was monitored in a combined excision/rescue assay as previously described in the Supplemental Experimental Procedures.
(A) The reaction scheme shows the relevant region of the primer and template. Extension of the primer in the presence of ddGTP or ACV-TP is indicated by the ‘‘Z’’
in red. The excision of a DNA chain terminator requires the presence of ATP as pyrophosphate donor. The 30-ultimate nucleotide (Z) was excised with ATP, and the
simultaneous presence of dGTP and ddTTP (in blue) allowed the rescue of DNA synthesis.
(B) The combined excision/rescue reaction was studied with ddGMP and ACV-MP-terminated primers. Z refers to the terminated primer and P to the rescued
product. The asterisk indicates dGMP misincorporation in the absence of the correct ddTTP substrate. Quantification of excision/rescue reactions for ddGMP
and ACV-MP are plotted. The concentration of the next complementary nucleotide required to inhibit 50% of the reaction is calculated on the basis of these two
curves. Note that ACV-MP-terminated primer excision/rescue reaction is inhibited due to dead-end complex formation.
(C) Incorporation of ACV-TP produces a dead-end complex with HIV-1 RT. Presented is site-specific footprinting of HIV-1 RT with ddGMP- and ACV-MP-ter-
minated primers in the presence of increasing concentrations of the next complementary nucleotide. Lanes –Fe and +Fe show control reactions in the absence
and presence of divalent Fe2+ ions that cause site-specific cleavage on the labeled template. The arrows and the sequence underneath the gel show the position
of the oxidative cleavage on the template strand at positions17 and18, which are indicative for post- and pretranslocated complexes, respectively. Note that,
for ACV-MP-terminated primer, no cleavage occurs at low next complementary nucleotide concentrations, indicating that the complex between RT and termi-
nated primer is fragile, whereas, at higher concentrations of the next complementary nucleotide, RT is blocked in a dead-end complex.
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K219Q express complete resistance to AZT and resulted to be
as sensitive to ACV in infected tissues as its parental HIV-1 var-
iant (Figure S3A). However, an HIV-1 isolate carrying the M184V
mutation (that confers resistance to Lamivudine) was less sensi-
tive to ACV than its parental strain (Figure S3B). The EC50 for the
M184V isolate was approximately four times higher than that for
the parental HIV-1 isolate. Thus, the evidence that a specific iso-
lated mutation of one amino acid in RT can reduce the sensitivity
of an HIV-1 isolate to ACV further proves that HIV-1 RT is tar-
geted and suppressed by ACV in human tissues, in agreement
with the data on ACV suppression of HIV-1 RT in cell-free sys-
tems.
DISCUSSION
Growing epidemics of HIV-1 infection, especially in countries
with limited resources, and the emergence of drug-resistant
viruses make it necessary to find ever new safe, efficient, and
inexpensive strategies against this virus. Strategies as effective
and safe as those developed against several other human path-
ogens such as HSV, which can be efficiently treated with ACV,
have yet to be developed against HIV. The antiherpetic specific-
ity of ACV is primarily based on the unique ability of HHV-
encoded kinases to phosphorylate ACV to its monophosphate
derivative, which is subsequently converted into the antivirally
active ACV-TP (Reardon and Spector, 1989). Consistent with
its highly restricted antiherpetic activity, ACV is not currently
used as a direct HIV-1 inhibitor.
Our findings demonstrate (1) the direct inhibitory effect of
ACV-TP, but not of ACV itself, on isolated HIV-1 RT in a cell-
free system, (2) the suppression of HIV-1 replication by ACV in
human tissues and in T cell lines if and only if they carry HHV
that phosphorylate ACV, and (3) the ability of a phosphorylated
ACV prodrug to bypass the requirement of HHV to suppress
HIV. Thus, we provide definitive experimental evidence of inhibi-
tion of HIV-1 RT activity by phosphorylated ACV and demon-
strate that ACV phosphorylation occurring in HHV-infected hu-
man tissues transforms this widely used antiherpetic drug into
an HIV-1 inhibitor.
The direct suppression of HIV-1 RT activity by ACV-TP was
demonstrated in two different cell-free assays, one using re-
combinant HIV-1 RT and the other using RT extracted from lysed
HIV-1 virions. We showed that ACV-TP is incorporated into the
nascent viral DNA chain with a level of efficiency similar to that
of its natural equivalent dGTP. Incorporation of ACV-TP results
in the termination of reverse transcription, while the excision of
the incorporated ACV-MP from the DNA chain is partially in-
hibited because of the fragility of the complex between HIV-1
RT and the terminated DNA chain or because of the formation
of a dead-end complex. These properties of ACV resemble those
of certain approved anti-HIV NRTIs (Marchand and Gotte, 2003;
Meyer et al., 1999), and we showed here that ACV-TP, a non-
phosphonate acyclic nucleoside analog, inhibits HIV-1 RT.
To further confirm that, in HIV-1-infected cells, ACV-triggered
HIV-1 suppression is mediated by RT, we identified a pair of iso-
genic HIV-1 strains differing only by one amino acid (M184V) in
RT but having different sensitivities to ACV in ex vivo human tis-
sues. Future studies on selection of ACV-resistant HIV-1 isolatesCell Host &and testing of various multidrug-resistant HIV-1 isolates for ACV
sensitivity will reveal the exact set of RT mutations associated
with reduced sensitivity to ACV and the rate of their evolution.
Identification of ACV-resistant mutants does not, in general, ex-
clude the use of ACV against HIV-1 variants resistant to other
NRTIs; for instance, ACV efficiently suppresses the replication
of AZT-resistant HIV-1.
As demonstrated in a cell-free system, to inhibit HIV-1 RT, ACV
has to be converted into ACV-TP. In human tissues, such con-
version requires HHV infection. Accordingly, we found that, in
the presence of HHVs that are capable of phosphorylating
ACV, HIV-1 was inhibited in ACV-treated tonsils, lymph nodes,
and cervico-vaginal and colorectal tissues, where the critical
events of HIV-1 pathogenesis and transmission occur in vivo.
Various HHVs, including the ubiquitous HHV-6 detected in all
but one tissue ex vivo, may mediate HIV-1 suppression by
ACV. The level of HHV-6 replication may be essential. In tonsillar
tissues, in which ACV inhibited HIV replication by more than
50%, the median HHV-6 load was significantly higher than in
the tissues in which ACV suppressed HIV replication by less
than 50%. Moreover, in tissues where the HIV-1 inhibition was
suboptimal, there was a correlation between the ACV-mediated
suppression of HIV-1 replication and the level of HHV-6. These
results demonstrate again the critical role of HHVs in ACV-medi-
ated suppression of HIV-1 and indicate the importance of HHV-6
in mediating HIV-1 suppression by ACV in our ex vivo tissue
system.
HHV-6 and HHV-7 are ubiquitous viruses, and, therefore, the
probability of finding an HHV-free tissue is very low. Neverthe-
less, by testing tissues from multiple donors, we identified one
tonsillar tissue that was not infected by any HHV. ACV did not
inhibit HIV-1 replication in this tissue.
However, to further demonstrate that HHVs are necessary and
sufficient for the anti-HIV effect of ACV, we used the HHV-unin-
fected MT4 cell line. Consistent with the proposed mechanism
based on HHV-mediated activation, ACV did not inhibit HIV rep-
lication in this HHV-free cell line. However, when HHV-6-infected
cells were added to the HIV-1-infected cultures, ACV became an
HIV-1 suppressor. This effect was dependent on both the con-
centration of ACV and the fraction of HHV-6-infected cells.
Apparently, in HHV reconstituted MT4 cultures, ACV that is
phosphorylated in HHV-6-infected cells is transferred to HIV-1-
infected cells, since the majority of these cells were not coin-
fected with HHV-6. These results are in full agreement with the
published data on the transfer of phosphorylated ACV between
cells (Burrows et al., 2002; Degreve et al., 1999). In tissues, trans-
fer of phosphorylated ACV between cells is facilitated by special-
ized contacts (Nicholas et al., 2003). These and probably other
factors (e.g., rapid proliferation and large endogenous dNTP
pools, as well as a high level of HIV-1 replication) may contribute
to a lower sensitivity of HIV-infected cell lines to ACV compared
with integral tissues.
To further demonstrate the necessity of ACV activation for HIV
suppression, we synthesized an already monophosphorylated
(activated) ACV in which the phosphate is masked by liphophilic
groups. In contrast to nonphosphorylated ACV, this prodrug
suppressed HIV-1 in HHV-free cultures of MT4 or CEM cells. Al-
though enzymatic reactions mediating ACV prodrug conversion
into its active form have been described (Congiatu et al., 2007),Microbe 4, 260–270, September 11, 2008 ª2008 Elsevier Inc. 267
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Nevertheless, our results provide strong evidence that, upon
phosphorylation, ACV suppresses HIV-1 replication in cells. Im-
portantly, these experiments also demonstrate the feasibility of
designing a new class of anti-HIV compounds. However, unlike
ACV (with a proven safety record and exhaustively studied phar-
macokinetics), ACV prodrug effects in various systems have to
be evaluated in order to form conclusions on their potential
clinical use.
In summary, the following mechanism seems to be responsi-
ble for ACV suppression of HIV-1 in human tissues ex vivo, the
majority of which carry one or several HHVs, including HHV-6:
ACV is monophosphorylated by herpesviral enzymes in HHV-in-
fected cells and then further converted to ACV-TP, which sup-
presses HIV by inhibiting HIV-1 RT, similarly to other NRTIs.
Our results suggest that ACV may be therapeutically beneficial
for various HIV-1-infected patients, since the majority of humans
are already infected with HHV-6, often together with other HHVs
that activate ACV at least during reactivation. In particular, in im-
munocompromised patients for whom HHV replication is fre-
quent, those HHVs that are not completely suppressed by ACV
(e.g., HHV-6) can continuously generate phosphorylated ACV
derivatives. The incomplete inhibition of HHV-6 by ACV con-
firmed in our experiments is consistent with the much higher
Ki of ACV-TP for HHV-6 DNA polymerase (UL69) compared
with that of HSV-2 or HSV-1 DNA polymerase (Bapat et al., 1989).
However, clinical trials are needed to test whether replication
of HHVs—in particular of HHV-6, which is typically maintained in
various organs, including the intestines and the vagina, even in
immunocompetent individuals (De Bolle et al., 2005)—would
be sufficient to suppress HIV-1 in ACV-treated individuals.
Also, clinical trials should reveal whether the range of ACV con-
centrations used in our study to suppress HIV-1 is clinically rele-
vant. Although ACV penetration efficiency and drug clearance
were unknown for ex vivo tissues, the calculated EC50 of 3.1 mM
was in the range of what was reported in vivo: a dose of 1 g of
oral valacyclovir per day results in a plasma peak concentration
of 29.5 mM, a minimum concentration in serum of 3 mM, and
a plasma concentration time curve of 89 mM/h ACV (Lycke
et al., 2003; Soul-Lawton et al., 1995). Moreover, the therapeutic
dose of the orally administered ACV prodrug valacyclovir, de-
pending on clinical indications, can be increased to as much
as 3 g per day.
Recent clinical trials performed so far are in agreement with
our ex vivo results and demonstrated that ACV is efficient in sup-
pressing HIV in HSV-2-coinfected individuals (Baeten et al.,
2007; Delany et al., 2007; Dunne et al., 2008; Nagot et al.,
2007; Zuckerman et al., 2007). Valacyclovir treatment, at the
dose of 1 g per day, reduced the HIV-1 plasma load in these in-
dividuals by 50%–70%, an effect comparable to that reported
here for human tissues infected with other HHVs. This HIV-1 viral
load reduction was clinically beneficial (Corey, 2007) and similar
to that reported for AZT or stavudine monotherapy (70%) (Delta
Coordinating Committee and Delta Virology Committee, 1999;
Katzenstein et al., 2000; Rey et al., 1998). In contrast to the es-
tablished ACV activity in reducing HIV load in HSV-2 coinfected
patients, recent trials failed to demonstrate that HSV-2 suppres-
sive therapy prevents acquisition of HIV-1 (Celum et al., 2008;
Cohen, 2007; Lisco and Vanpouille, 2008; Watson-Jones et al.,268 Cell Host & Microbe 4, 260–270, September 11, 2008 ª2008 El2008). However, none of the approved NTRIs widely used for
therapy was yet developed into an efficient preventive drug
when used alone.
Our results provide new insights into the effect of ACV in HIV-
1-infected patients. In all previous trials, the effect of ACV on
HIV-1 was considered to be indirect and due to the suppression
of HSV-2-mediated inflammation. Here, we demonstrate that
ACV directly suppresses HIV-1 RT in HHV-coinfected tissue.
This effect depends on the levels of HHVs, which were not eval-
uated in these clinical trials or in previous in vitro studies (Resnick
et al., 1986). Obviously, the results obtained in tissues ex vivo
should be extrapolated to the in vivo situation with caution. How-
ever, the reliance on lymphotropic HHVs to create the active HIV
suppressor at the site of HIV replication may, in principle, solve
the critical pharmacological problem of drug delivery.
In conclusion, our data on HIV-infected tissues coinfected with
various HHVs suggest that ACV may be used to decrease the
HIV load in both the peripheral blood and the genital compart-
ments of patients infected with one or several HHVs, including
the highly prevalent HHV-6 (Campadelli-Fiume et al., 1999). Al-
though the magnitude of HIV-1 suppression by ACV as well as
by the currently approved NRTIs is too low to be used in mono-
therapy, it is sufficient to be an important part of drug cocktails.
In general, the combination of ACV with an endogenous HHV
infection to suppress HIV may constitute a new principle of anti-
HIV therapy—a ‘‘binary weapon’’ in which one inert component
is converted by another endogenous component into an active
therapeutic compound. In the case of ACV, its exceptionally
low toxicity and the low cost of ACV and related drugs that
have been safely used in humans for more than 30 years, as
well as their existing formulations as pills and creams, make
them potentially applicable for HIV treatment, possibly in combi-
nation with other drugs. New targeted clinical trails will test
whether ACV and its derivatives can be used for this new pur-
pose in line with a popular trend to identify new uses for old drugs
(Chong and Sullivan, 2007).
EXPERIMENTAL PROCEDURES
Tissue and Cell Culture
Tonsillar tissues from routine surgery were obtained from the Children’s Na-
tional Medical Center (Washington, DC). Lymph nodes and colorectal and cer-
vicovaginal tissues were obtained either from routine surgery or from cadavers
through the National Disease Research Interchange (Philadelphia, PA). All tis-
sues were obtained according to IRB-approved protocols. Tissues were dis-
sected into 2 mm3 blocks and cultured as described earlier (Fletcher et al.,
2006; Glushakova et al., 1995; Grivel et al., 2007). MT4 cells were obtained
from the American Type Culture Collection (Manassas, VA) and cultured in
RPMI 1640 medium with 10% heat-inactivated FCS.
Viral Infections
Tissue inoculation with HIV-1 and HHV-6B was performed as described earlier
(Grivel et al., 2007). For further details, see the Supplemental Experimental
Procedures.
ACV and ACV Monophosphorylated Prodrug Treatment
ACV pharmaceutical formulations for intravenous infusion (Bedford Laborato-
ries, Bedford, OH; NDC 55390-612-10) were diluted in distilled water and used
at the indicated concentrations. A different pharmaceutical formulation for in-
travenous infusion (American Pharmaceutical Partners, Schaumburg, IL; NDC
63323-325-10) and a commercial preparation of ACV (Sigma-Aldrich, St.
Louis, MO) were tested for HIV-1 suppression in matched tonsillar tissuessevier Inc.
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ACV prodrug-acyclovir-(1-naphthyl [methoxy-L-alaninyl]) phosphoramidate
(Cf2649) is described in the Supplemental Experimental Procedures. Com-
pounds were added to the culture medium 12 hr prior to HIV-1 infection and
again at each culture medium change.
Real-Time PCR
The HHV load and the HIV-1 proviral load in tissues were determined by mea-
surement of the number of viral DNA copies. DNA from two blocks of tissue
was extracted with the QIAamp kit (QIAGEN GmbH, Hilden, Germany) accord-
ing to the manufacturer’s instructions. For further details on real-time PCR
TaqMan assay, primers, and probes sequences, see the Supplemental Exper-
imental Procedures.
Exogenous Template RT Assay
Exogenous template HIV-1 RT assays were performed as described previ-
ously (Gorelick et al., 1990), with modifications specified in the Supplemental
Experimental Procedures.
Steady-State Kinetics, ATP-Dependent Excision, and Site-Specific
Footprinting
These assays were performed as described previously (Gotte et al., 1998;
Marchand and Gotte, 2003; Marchand et al., 2007) with modifications speci-
fied in the Supplemental Experimental Procedures.
Statistical Analysis
Each datum point is the result of analysis of sets of 9 to 27 tissue blocks de-
rived from each of n donors, where n is indicated in the text. Since the absolute
level of HIV-1 replication varied from donor to donor, for every experiment, we
compared these levels using data from matched control blocks as the basis of
normalization. This allowed us to pool results obtained from tissues from differ-
ent donors. We analyzed these data using a two-tailed paired Student’s t test.
Because the distribution of the numbers of HHV-6 and HIV-1 (proviral) DNA
equivalents failed the Kolmogorov-Smirnov normality test, we used distribu-
tion-free nonparametric methods (Wilcoxon Match-Pairs, Signed-Ranks
Test, and Mann-Whitney U test) to evaluate the significance of the differences
between various experimental groups. However, when these data were log10
transformed, the normality was achieved and we applied parametric methods
(paired or unpaired Student’s t test). The statistical significance of differences
between data from various experimental groups evaluated after transforma-
tion was similar to that evaluated with nonparametric methods applied to non-
transformed results. Depending on the type of statistical analysis, the pooled
data are presented either as means ± standard error of the mean (SEM) or as
median and interquartile range (IQR). All of the hypothesis tests were two-
tailed, and a p value of% 0.05 defined statistical significance.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, three
figures, and one table and can be found with this article online at http://www.
cellhostandmicrobe.com/cgi/content/full/4/3/260/DC1/.
ACKNOWLEDGMENTS
We thank Dr. M. Santi and the entire staff of the Department of Pathology of
Children’s National Medical Center for their generous assistance in obtaining
human tonsillar tissues.
This research was supported, in part, by the Intramural Research Program of
the Eunice Kennedy Shriver National Institute of Child Health and Human De-
velopment, NIH, and by federal funds from the National Cancer Institute, NIH,
under contract NO1-CO-12400. R.F.S. is supported, in part, by NIH grants
5P30-AI-50409 (CFAR), 5R37-AI-041980, and the Department of Veterans
Affairs. J.B. is supported by the Geconcerteerde Onderzoeksacties (GOA
No. 05/19). M.G. is the recipient of a national career award and a research
grant from the Canadian Institutes of Health Research. L.M. dedicates this
paper to the 80th birthday of his mentor, Professor Ju. M. Vasiliev.Cell HostReceived: April 28, 2008
Revised: June 15, 2008
Accepted: July 16, 2008
Published: September 10, 2008
REFERENCES
Baeten, J.M., Strick, L., Lucchetti, A., Whittington, W.L.H., Sanchez, J.,
Coombs, R.W., Margaret, A., Wald, A., Corey, L., Celum, C. (2007). Herpes
simplex virus suppressive treatment decreases plasma HIV-1 load in HSV-2/
HIV-1 co-infected: a randomised, placebo-controlled, cross-over trial, In
17th International Society for Sexually Transmitted Diseases Research
Meeting, July 27–August 1, 2007 (Seattle, WA).
Bapat, A.R., Bodner, A.J., Ting, R.C., and Cheng, Y.C. (1989). Identification
and some properties of a unique DNA polymerase from cells infected with hu-
man B-lymphotropic virus. J. Virol. 63, 1400–1403.
Barral, K., Hider, R.C., Balzarini, J., Neyts, J., De Clercq, E., and Camplo, M.
(2003). Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-
one dideoxynucleoside derivatives. Bioorg. Med. Chem. Lett. 13, 4371–4374.
Burrows, F.J., Gore, M., Smiley, W.R., Kanemitsu, M.Y., Jolly, D.J., Read, S.B.,
Nicholas, T., and Kruse, C.A. (2002). Purified herpes simplex virus thymidine
kinase retroviral particles: III. Characterization of bystander killing mechanisms
in transfected tumor cells. Cancer Gene Ther. 9, 87–95.
Campadelli-Fiume, G., Mirandola, P., and Menotti, L. (1999). Human herpesvi-
rus 6: An emerging pathogen. Emerg. Infect. Dis. 5, 353–366.
Celum, C., Wald, A., Hughes, J., Sanchez, J., Reid, S., Delany-Moretlwe, S.,
Cowan, F., Casapia, M., Ortiz, A., Fuchs, J., et al. (2008). Effect of aciclovir
on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men
who have sex with men: a randomised, double-blind, placebo-controlled trial.
Lancet 371, 2109–2119.
Chong, C.R., and Sullivan, D.J., Jr. (2007). New uses for old drugs. Nature 448,
645–646.
Cohen, M.S. (2004). HIV and sexually transmitted diseases: lethal synergy.
Top. HIV Med. 12, 104–107.
Cohen, J. (2007). AIDS research. Promising prevention interventions perform
poorly in trials. Science 317, 440.
Congiatu, C., Brancale, A., and McGuigan, C. (2007). Molecular modelling
studies on the binding of some protides to the putative human phosphorami-
dase Hint1. Nucleosides Nucleotides Nucleic Acids 26, 1121–1124.
Corey, L. (2007). Synergistic copathogens–HIV-1 and HSV-2. N. Engl. J. Med.
356, 854–856.
Corey, L., Wald, A., Celum, C.L., and Quinn, T.C. (2004). The effects of herpes
simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlap-
ping epidemics. J. Acquir. Immune Defic. Syndr. 35, 435–445.
De Bolle, L., Naesens, L., and De Clercq, E. (2005). Update on human herpes-
virus 6 biology, clinical features, and therapy. Clin. Microbiol. Rev. 18, 217–
245.
De Clercq, E., Naesens, L., De Bolle, L., Schols, D., Zhang, Y., and Neyts, J.
(2001). Antiviral agents active against human herpesviruses HHV-6, HHV-7
and HHV-8. Rev. Med. Virol. 11, 381–395.
Degreve, B., De Clercq, E., and Balzarini, J. (1999). Bystander effect of purine
nucleoside analogues in HSV-1 tk suicide gene therapy is superior to that of
pyrimidine nucleoside analogues. Gene Ther. 6, 162–170.
Delany, S., Mayaud, P., Clayton, T., Mlaba, N., Akpomiemie, G., Hira, K., Ca-
povilla, A., Stevens, W., and Rees, W. (2007). Impact of HSV-2 suppressive
therapy on genital and plasma HIV-1 RNA in HIV-1 and HSV-2-seropositive
women not taking ART: a randomized, placebo-controlled trial in Johannes-
burg, South Africa. In 14th Conference on Retroviruses and Opportunistic In-
fections, February 25-28, 2007 (Los Angeles, CA).
Delta Coordinating Committee and Delta Virology Committee (1999). HIV-1
RNA response to antiretroviral treatment in 1280 participants in the Delta Trial:
an extended virology study. AIDS 13, 57–65.
Dunne, E.F., Whitehead, S., Sternberg, M., Thepamnuay, S., Leelawiwat, W.,
McNicholl, J.M., Sumanapun, S., Tappero, J.W., Siriprapasiri, T., and& Microbe 4, 260–270, September 11, 2008 ª2008 Elsevier Inc. 269
Cell Host & Microbe
Acyclovir Inhibits HIV-1 Reverse TranscriptaseMarkowitz, L. (2008). Suppressive acyclovir therapy reduces HIV cervicovagi-
nal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J. Ac-
quir. Immune Defic. Syndr. 49, 77–83.
Elion, G.B. (1983). The biochemistry and mechanism of action of acyclovir. J.
Antimicrob. Chemother. 12 (Suppl B), 9–17.
Fletcher, P.S., Elliott, J., Grivel, J.C., Margolis, L., Anton, P., McGowan, I., and
Shattock, R.J. (2006). Ex vivo culture of human colorectal tissue for the evalu-
ation of candidate microbicides. AIDS 20, 1237–1245.
Freeman, E.E., Weiss, H.A., Glynn, J.R., Cross, P.L., Whitworth, J.A., and
Hayes, R.J. (2006). Herpes simplex virus 2 infection increases HIV acquisition
in men and women: systematic review and meta-analysis of longitudinal
studies. AIDS 20, 73–83.
Glushakova, S., Baibakov, B., Margolis, L.B., and Zimmerberg, J. (1995). In-
fection of human tonsil histocultures: a model for HIV pathogenesis. Nat.
Med. 1, 1320–1322.
Gorelick, R.J., Nigida, S.M., Jr., Bess, J.W., Jr., Arthur, L.O., Henderson, L.E.,
and Rein, A. (1990). Noninfectious human immunodeficiency virus type 1 mu-
tants deficient in genomic RNA. J. Virol. 64, 3207–3211.
Gotte, M., Maier, G., Gross, H.J., and Heumann, H. (1998). Localization of the
active site of HIV-1 reverse transcriptase-associated RNase H domain on
a DNA template using site-specific generated hydroxyl radicals. J. Biol.
Chem. 273, 10139–10146.
Grivel, J.C., Elliott, J., Lisco, A., Biancotto, A., Condack, C., Shattock, R.J.,
McGowan, I., Margolis, L., and Anton, P. (2007). HIV-1 pathogenesis differs
in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and
CXCR4-tropic HIV-1. AIDS 21, 1263–1272.
Ioannidis, J.P., Collier, A.C., Cooper, D.A., Corey, L., Fiddian, A.P., Gazzard,
B.G., Griffiths, P.D., Contopoulos-Ioannidis, D.G., Lau, J., Pavia, A.T., et al.
(1998). Clinical efficacy of high-dose acyclovir in patients with human immuno-
deficiency virus infection: a meta-analysis of randomized individual patient
data. J. Infect. Dis. 178, 349–359.
Jacobson, M.A., and Mills, J. (1988). Serious cytomegalovirus disease in the
acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis,
and treatment. Ann. Intern. Med. 108, 585–594.
Katzenstein, D.A., Hughes, M., Albrecht, M., Hammer, S., Para, M., Murphy,
R., Valdez, H., Haubrich, R., and Liou, S. (2000). Virologic and CD4+ cell re-
sponses to new nucleoside regimens: switching to stavudine or adding lami-
vudine after prolonged zidovudine treatment of human immunodeficiency vi-
rus infection. ACTG 302 Study Team. AIDS Clinical Trials Group. AIDS Res.
Hum. Retroviruses 16, 1031–1037.
Lisco, A., and Vanpouille, C. (2008). HSV-2 suppression and the incidence of
HIV. N. Engl. J. Med. 359, 535.
Lusso, P., and Gallo, R.C. (1994). Human herpesvirus 6 in AIDS. Lancet 343,
555–556.
Lycke, J., Malmestrom, C., and Stahle, L. (2003). Acyclovir levels in serum and
cerebrospinal fluid after oral administration of valacyclovir. Antimicrob. Agents
Chemother. 47, 2438–2441.
Marchand, B., and Gotte, M. (2003). Site-specific footprinting reveals differ-
ences in the translocation status of HIV-1 reverse transcriptase. Implications270 Cell Host & Microbe 4, 260–270, September 11, 2008 ª2008 Elsfor polymerase translocation and drug resistance. J. Biol. Chem. 278,
35362–35372.
Marchand, B., Tchesnokov, E.P., and Gotte, M. (2007). The pyrophosphate an-
alogue foscarnet traps the pre-translocational state of HIV-1 reverse transcrip-
tase in a Brownian ratchet model of polymerase translocation. J. Biol. Chem.
282, 3337–3346.
Meyer, P.R., Matsuura, S.E., So, A.G., and Scott, W.A. (1998). Unblocking of
chain-terminated primer by HIV-1 reverse transcriptase through a nucleo-
tide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95, 13471–13476.
Meyer, P.R., Matsuura, S.E., Mian, A.M., So, A.G., and Scott, W.A. (1999). A
mechanism of AZT resistance: an increase in nucleotide-dependent primer un-
blocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4, 35–43.
Nagot, N., Ouedraogo, A., Foulongne, V., Konate, I., Weiss, H.A., Vergne, L.,
Defer, M.C., Djagbare, D., Sanon, A., Andonaba, J.B., et al. (2007). Reduction
of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N. Engl. J.
Med. 356, 790–799.
Nicholas, T.W., Read, S.B., Burrows, F.J., and Kruse, C.A. (2003). Suicide
gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is en-
hanced with connexins to improve gap junctions and bystander effects. Histol.
Histopathol. 18, 495–507.
Reardon, J.E., and Spector, T. (1989). Herpes simplex virus type 1 DNA poly-
merase. Mechanism of inhibition by acyclovir triphosphate. J. Biol. Chem. 264,
7405–7411.
Resnick, L., Markham, P.D., Veren, K., Salahuddin, S.Z., and Gallo, R.C.
(1986). In vitro suppression of HTLV-III/LAV infectivity by a combination of acy-
clovir and suramin. J. Infect. Dis. 154, 1027–1030.
Rey, D., Hughes, M., Pi, J.T., Winters, M., Merigan, T.C., and Katzenstein, D.A.
(1998). HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immu-
nologic and virologic responses to zidovudine. The AIDS Clinical Trials Group
Study 175 Virology Team. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17,
203–208.
Schacker, T., Zeh, J., Hu, H., Shaughnessy, M., and Corey, L. (2002). Changes
in plasma human immunodeficiency virus type 1 RNA associated with herpes
simplex virus reactivation and suppression. J. Infect. Dis. 186, 1718–1725.
Soul-Lawton, J., Seaber, E., On, N., Wootton, R., Rolan, P., and Posner, J.
(1995). Absolute bioavailability and metabolic disposition of valaciclovir, the
L-valyl ester of acyclovir, following oral administration to humans. Antimicrob.
Agents Chemother. 39, 2759–2764.
Watson-Jones, D., Weiss, H.A., Rusizoka, M., Changalucha, J., Baisley, K.,
Mugeye, K., Tanton, C., Ross, D., Everett, D., Clayton, T., et al. (2008). Effect
of herpes simplex suppression on incidence of HIV among women in Tanzania.
N. Engl. J. Med. 358, 1560–1571.
Zuckerman, R.A., Lucchetti, A., Whittington, W.L., Sanchez, J., Coombs, R.W.,
Zuniga, R., Magaret, A.S., Wald, A., Corey, L., and Celum, C. (2007). Herpes
simplex virus (HSV) suppression with valacyclovir reduces rectal and blood
plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, dou-
ble-blind, placebo-controlled crossover trial. J. Infect. Dis. 196, 1500–1508.evier Inc.
